



**D C Betticher**

**Contact**

D C Betticher

## Publications (9)

König D, Scharl S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild S, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet E, Hayoz S, Thierstein S, Betticher D, Ris H, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. *ESMO Open* 2022; 7:100455.

Koeberle D, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). *Ann Oncol* 2015; 26:709-14.

Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). *Lung Cancer* 2014; 85:306-13.

Betticher D, Cerny T, Maibach R, Cina S, Cogliatti S, Kovascovics T, von Rohr A, Beck J, Aulitzky W, Kaiser U, Dyer M, Kaufmann M, Radford J, Martinelli G, Linch D. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2006; 17:1546-52.

Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. *British journal of cancer* 2006; 94:1099-106.

Strasser F, Betticher D, Suter T. Trastuzumab and breast cancer. *N Engl J Med* 2001; 345:996.

Sonderegger T, Betticher D, Cerny T, Lauterburg B. Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. *Cancer chemotherapy and pharmacology* 2000; 46:40-2.

Ghielmini M, Bertoni F, Schmitter D, Lohri A, Wernli M, Stupp R, Betticher D, Pichert G, Bürki K, Schmitz S, Cerny T. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. *Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2000; 11 Suppl 1:123-6.

Calderoni A, Cerny T, Betticher D. [Is there progress in the chemotherapy of small cell lung cancer?]. *Schweizerische medizinische Wochenschrift* 1999; 129:1313-20.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)